Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zomedica ( (ZOMDF) ) has issued an announcement.
Zomedica announced a 16% increase in revenue for the third quarter of 2025, reaching $8.1 million, marking its highest quarterly revenue to date. The growth was driven by strong demand for its therapeutic devices and diagnostic products, alongside the introduction of a new Development Services revenue stream. The company reported a 51% growth in its Diagnostics segment and expanded its international presence through strategic partnerships. Zomedica’s efforts in cost reduction and infrastructure optimization have improved efficiency and positioned the company for sustainable growth and profitability.
The most recent analyst rating on (ZOMDF) stock is a Buy with a $0.25 price target. To see the full list of analyst forecasts on Zomedica stock, see the ZOMDF Stock Forecast page.
Spark’s Take on ZOMDF Stock
According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.
Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.
To see Spark’s full report on ZOMDF stock, click here.
More about Zomedica
Zomedica is an animal health company that provides point-of-care diagnostic and therapeutic products for equine and companion animals. The company focuses on innovative solutions such as the PulseVet and Assisi therapeutic devices, as well as the TRUFORMA diagnostic platform, aiming to serve veterinarians and pet owners globally.
Average Trading Volume: 1,939,533
Technical Sentiment Signal: Sell
Current Market Cap: $74.57M
See more data about ZOMDF stock on TipRanks’ Stock Analysis page.